GlobeNewswire
-
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
19/11/2026 -
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
19/11/2026 -
Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
19/11/2026 -
Korro to Participate in Upcoming Investor Conferences
19/11/2026 -
Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
19/11/2026 -
Evaxion announces strategy and business update and third quarter 2026 financial results
19/11/2026 -
In a Co-Managed Customer Support Model, Growing Companies Can Keep Control of Training While a Partner Runs Staffing
19/11/2026 -
Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
19/11/2026 -
Verano Celebrates Grand Opening of MÜV Tarpon Springs, the Company’s 89th Florida Location, 166th Nationwide
19/11/2026 -
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
19/11/2026 -
Enable Injections and ARespo Biopharma Announce Strategic Partnership
19/11/2026 -
J-Star Holding Expands Mitsubishi Chemical Partnership to Advance U.S. UAV Manufacturing and Domestic Carbon Fiber Supply Chain
19/11/2026 -
Axsome Therapeutics to Participate in Upcoming Investor Conferences
19/11/2026 -
Interim Results for the Third Quarter of 2026 - BioPorto reports continued NGAL growth and advances the U.S. Adult Validation Study
19/11/2026 -
Scancell Provides Corporate and Clinical Update
19/11/2026 -
DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
19/11/2026 -
AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads
19/11/2026 -
ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector
19/11/2026 -
Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
19/11/2026
Pages